Akari TX

NEW YORK and LONDON, March 21, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative …

[Read more...] about Akari Therapeutics to Present on Two Ongoing Programs Covering Age-Related Macular Degeneration and Diseases of the Surface of the Eye at The Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting

Broad-acting antihistamine has potential in number of disease areas with unmet clinical need NEW YORK and LONDON, March 09, 2022 (GLOBE NEWSWIRE) -- Akari …

[Read more...] about Akari Therapeutics Announces New Data Supporting Use of Drug Candidate Votucalis Targeting Difficult to Treat Pain and Itch

NEW YORK and LONDON, March 8, 2022 – Akari Therapeutics, Plc (Nasdaq: AKTX) (“Akari” or the “Company”), a biopharmaceutical company focused on innovative …

[Read more...] about Akari Therapeutics, Plc Announces $9.0 Million Registered Direct Offering

Industry veteran brings extensive experience in the development and commercialization of advanced biological therapies, including in the field of …

[Read more...] about Akari Therapeutics Appoints Rachelle Jacques as President and Chief Executive Officer

Akari’s complement and leukotriene inhibitor, nomacopan, demonstrated improved survival (80% vs. 30%) in a preclinical model of traumaA follow-on program …

[Read more...] about Akari Therapeutics Announces New Data Showing A Significant Role for Complement Activation in the Clinical Outcomes of U.S. Army Trauma Patients in Iraq and the Therapeutic Potential of Nomacopan for Treatment of Trauma